高德紅外(002414.SZ):半年度淨利潤預增734.73%–957.33%
格隆匯7月11日丨高德紅外(002414.SZ)公佈2025年半年度業績預告,1-6月公司實現歸屬於上市公司股東的淨利潤盈利1.5億元–1.9億元,比上年同期上升734.73%–957.33%;扣除非經常性損益後的淨利潤盈利1.3億元–1.7億元,比上年同期上升13458.61%–17630.50%;基本每股收益盈利0.0351元/股–0.0445元/股。
報告期內,原延期的型號項目類產品恢復交付,且與某貿易公司簽訂的完整裝備系統總體外貿產品合同已完成國外驗收交付,同時公司大力擴展民品領域,紅外芯片應用業務需求快速釋放,營業收入大幅增長,銷售規模的增長帶來利潤同步增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.